NeuroPace, Inc.

NPCE Healthcare Medical Devices

In the quarter to June 2026, revenue grew 17.1%, EPS grew 30.8%, free cash flow fell 78.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

12.24 0.54 −4.23%
Market cap
$438.7M
P/E
0.0×
Fwd P/E
−27.1×
Dividend yield
—
F-score
5/9
Altman Z
−2.52
Beneish M
−2.88
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

5 5 5 5
ROE
(169.27%) (158.74%) (111.38%) (122.05%)
ROA
(23.57%) (21.44%) (20.63%) (18.82%)
ROIC
(70.97%) (60.58%) (53.73%) (44.64%)
Return on Tangible Assets
(31.22%) (27.74%) (29.91%) (27.30%)
Average Days of Receivables
60.02 47.22 54.23 52.98
Free Cash Flow per Share
(0.50) (0.35) (0.29) (0.34)
Free Cash Flow
(16.58) (11.34) (9.84) (11.61)
Other line items

Show all line items

Columns are period end dates